FDA Investigator

Gabriel Bermudez-Picart

Latest inspection on record: Mount Prospect, United States, June 2026 · records back to 2024

Human DrugsAnimal Drugs & Feeds

FDA inspection record · Last updated August 15, 2026

Overview

  • 21 inspections across 20 sites are on record.
  • 15 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2026-06-16.

At a glance

Inspections

21

Sites

20

Observations

15

Career since

Mar 2024

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Xttrium Laboratories, Inc.16 Jun 2026Human DrugsOn file
Topical Pharmaceuticals, Inc.7 May 2026Human DrugsView 483 →
AbbVie Inc.27 Apr 2026Human Drugs
SGS North America Inc.20 Mar 2026Human DrugsView 483 →
Particle Technology Group, LLC20 Feb 2026Human Drugs

Sites inspected

Xttrium Laboratories, Inc.Mount Prospect, United States1 insp.
Topical Pharmaceuticals, Inc.Addison, United States1 insp.
AbbVie Inc.North Chicago, United States1 insp.
SGS North America Inc.Lincolnshire, United States1 insp.
Particle Technology Group, LLCDowners Grove, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Robert J Ham2 shared
Chikitsa S Patel1 shared
Scott D Mcgrew1 shared

Full investigator report

Get the verbatim findings behind Gabriel Bermudez-Picart's 15 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site